atai Impact Establishes the atai Fellowship Fund in Psychedelic Neuroscience with Massachusetts General Hospital’s… Dec 16, 2021
Apeiron and Other Key Shareholders of atai Life Sciences Reinforce Support by Entering into Extended, Voluntary Share… Dec 15, 2021
After 283 Days, Health Minister (Finally) Grants Psilocybin Exemptions To Three Canadians With Mental Health Conditions Dec 14, 2021
COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in… Dec 13, 2021
